Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark.
Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark.
J Am Coll Cardiol. 2022 Apr 26;79(16):1565-1575. doi: 10.1016/j.jacc.2022.02.024.
The relationship between exercise hemodynamics, loading conditions, and medical treatment in patients with obstructive hypertrophic cardiomyopathy (HCM) is incompletely understood.
This study aimed to investigate the effect of metoprolol on invasive hemodynamic parameters at rest and during exercise in patients with obstructive HCM.
This randomized, double-blind, placebo-controlled crossover trial enrolled 28 patients with obstructive HCM and New York Heart Association functional class ≥II. Patients were randomized to initiate either metoprolol 150 mg or placebo for 2 consecutive 2-week periods. Right-heart catheterization and echocardiography were performed at rest and during exercise at the end of each treatment period. The primary outcome was the difference in pulmonary capillary wedge pressure (ΔPCWP) between peak exercise and rest.
No treatment effect on ΔPCWP was observed between metoprolol and placebo treatment (21 ± 9 mm Hg vs 23 ± 9 mm Hg; P = 0.12). At rest, metoprolol lowered heart rate (P < 0.0001), left ventricular outflow tract (LVOT) gradient (P = 0.01), and increased left ventricular end-diastolic volume (P = 0.02) and stroke volume (SV) (+6.4; 95% CI: 0.02-17.7; P = 0.049). During peak exercise, metoprolol was associated with a lower heart rate (P < 0.0001), a lower LVOT gradient (P = 0.0005), lesser degree of mitral regurgitation (P = 0.004), and increased SV (+9 mL; 95% CI: 2-15 mL; P = 0.008).
In patients with obstructive HCM, exercise was associated with an abnormal rise in PCWP, which was unaffected by metoprolol. However, metoprolol increased SV at rest and peak exercise following changes in end-diastolic volume, LVOT gradient, and degree of mitral regurgitation. (The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy [TEMPO]; NCT03532802).
运动血液动力学、负荷条件与梗阻性肥厚型心肌病(HCM)患者的药物治疗之间的关系尚未完全阐明。
本研究旨在探讨美托洛尔对梗阻性 HCM 患者静息和运动时的有创血液动力学参数的影响。
这是一项随机、双盲、安慰剂对照的交叉试验,纳入了 28 例纽约心脏协会功能分级≥Ⅱ级的梗阻性 HCM 患者。患者被随机分为连续 2 个 2 周的美托洛尔 150mg 或安慰剂治疗期。在每个治疗期末,进行右心导管检查和超声心动图检查,以评估静息和运动时的情况。主要结局是运动峰值时与静息时的肺毛细血管楔压(PCWP)差值。
美托洛尔和安慰剂治疗之间的 PCWP 差值无治疗效果(21±9mmHg 比 23±9mmHg;P=0.12)。在静息状态下,美托洛尔降低了心率(P<0.0001)、左心室流出道(LVOT)梯度(P=0.01),并增加了左心室舒张末期容积(P=0.02)和每搏量(SV)(+6.4;95%CI:0.02-17.7;P=0.049)。在运动峰值时,美托洛尔与较低的心率(P<0.0001)、较低的 LVOT 梯度(P=0.0005)、较轻的二尖瓣反流(P=0.004)和增加的 SV(+9mL;95%CI:2-15mL;P=0.008)相关。
在梗阻性 HCM 患者中,运动与 PCWP 的异常升高相关,而美托洛尔对此无影响。然而,美托洛尔增加了静息和运动时的 SV,这与舒张末期容积、LVOT 梯度和二尖瓣反流程度的变化有关。(肥厚型梗阻性心肌病患者中美托洛尔的作用 [TEMPO];NCT03532802)。